DOI: 10.36347/sjmcr.2021.v09i10.012

Pages: 971-973

COVID-19-related hypercoagulability state resulting in thromboembolic events is widely described in critically ill patients, especially in those hospitalized in the intensive care unit. Nevertheless, these thrombotic events are uncommon in COVID-19-patients with mild disease. Herein we present the case of a 51-year-old male admitted for pulmonary embolism who previously presented a mild COVID-19 twenty days earlier. He was discharged on Rivaroxaban. This finding raises discussion about extending prophylactic anticoagulation in selected patients with mild COVID-19 at a high risk of VTE.